Harnessing the Power of the Poliovirus as a Cancer Cure

brain_tumor

Polio, a highly infectious and crippling disease, was certainly one of the most feared viruses in the 20th century. Each year, thousands of children were left paralyzed. Polio has been successfully eliminated in the U.S. for decades due to a widespread vaccine program. So why would a group of researchers be interested in injecting the […]

Biosimilars in 2015: What Can We Expect?

On Friday, March 6th, 2015 the FDA approved Sandoz’s Zarxio, the first official biosimilar that will be made available in the U.S. Zarxio, a recombinant granulocyte colony-stimulating factor used to boost white blood cells after cancer treatments, is the long-awaited biosimilar for filgrastim (Amgen’s Neupogen). The FDA noted in their briefs that Zarxio was “highly […]

Drugs.com Adds Mayo Clinic Disease Reference

Drugs.com is pleased to announce it has licensed select content from Mayo Clinic to provide more timely and trustworthy medical condition and disease information. The articles include detailed information about medical diseases such as allergies, back pain, depression, erectile dysfunction, and type 2 diabetes. Each article includes informative sections which may include an overview, symptoms, when […]

Fox News Features Drugs.com Medication Guide app

Thanks to Fox News for showcasing the Drugs.com Medication Guide app today. Very much appreciated. Available in both the Apple App store and the Google Play store, this is a great app for ultra-quick research and/or keeping track of multiple meds. Check out the video at the link below… http://www.foxnews.com/health/2014/07/13/drugscom-app-provides-medical-information-on-go/ And check out the apps here… http://www.drugs.com/apps/

Consumer Reports Gives the Thumbs Up to the Drugs.com Pill Identifier App

screen568x568

Consumer Reports just put out a review of seven pill identifier apps. Here’s a snippet… “We reviewed seven apps that can help identify the pills you take, and liked two of them a lot: Drugs.com Pill Identifier and Epocrates Pill ID. The others—CVS/Pharmacy Pill Identifier, iPharmacy Pill Identifier, Pill Finder, Prescription Pill Identifier, and ID […]

Introducing the Drugs.com redesign

drugs_icon_050314

After a lot of effort from our NY brand agency and in-house designers, we have started to roll out a new look for Drugs.com. First step is a logo and menu change. At the same time we have a team working through updating all the mobile apps, Facebook, Google+, Twitter and Youtube channels. Wow, we’re […]

Q4 2013 Drug Sales Data Released: Tecfidera Growth On a Rapid Transit

Drugs.com has released the latest U.S. drug sales data. While the ranking of the top three drugs by sales — Abilify, Nexium and Humira — remains the same, Lilly’s Cymbalta drops from fourth to seventh and forfeits close to $319 million in sales due to generic availability. Nexium’s growth tapers too, possibly due to looming […]

Drugs.com and TrialReach to Give Patients Access to Drugs In Development

Drugs.com, the leading online clinical drug resource, and TrialReach are partnering to provide patients with information and access to treatments that are still under development. This partnership will bring TrialReach’s patient-centric content and tools directly to the 25+ million people who visit Drugs.com every month. From a patient’s perspective, clinical trials offer more treatment options […]

Looking Back at 2013

The end of the year is always a good time to reflect back on healthcare innovations, major drug approvals, and frankly, things that could have possibly gone a tad bit better. From advances in hepatitis C virus treatments, to over-the-counter availability of emergency contraception, the year had lots of positive healthcare hits. But a few […]

Q3 2013 Drug Sales Data Released: Top Five Drugs Each Post Over $1 Billion in Sales

The latest U.S. drug sales data has been released by Drugs.com. Rankings for the top five drugs by sales remain unchanged in the third quarter. Otsuka’s antipsychotic Abilify and AstraZeneca’s Nexium retain their number one and two spots, respectively. Nexium, the top proton pump inhibitor faces sizable over-the-counter competition, a looming Rx-to-OTC switch, and patent […]